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Abstract
Rationale  and  objectives:  To  assess  the  prostate  T2  value  as  a  predictor  of  malignancy  on  two
different  3  T  scanners.
Patients  and  methods:  Eighty-three  pre-prostatectomy  multiparametric  MRIs  were  retrospec-
tively evaluated  [67  obtained  on  a  General  Electric  MRI  (scanner  1)  and  16  on  a  Philips  MRI
(scanner 2)].  After  correlation  with  prostatectomy  specimens,  readers  measured  the  T2  value
of regions-of-interest  categorized  as  ‘‘cancers’’,  ‘‘false  positive  lesions’’,  or  ‘‘normal  tissue’’.
Results: On  scanner  1,  in  PZ,  cancers  had  signiﬁcantly  lower  T2  values  than  false  positive  lesions
(P =  0.02)  and  normal  tissue  (P  =  2  ×  10−9).  Gleason  ≥  6  cancers  had  similar  T2  values  than  false
positive lesions  and  signiﬁcantly  higher  T2  values  than  Gleason  ≥  7  cancers  (P  =  0.009).  T2  values
corresponding  to  a  25%  and  75%  risk  of  Gleason  ≥  7  malignancy  were  respectively  132  ms  (95%
CI: 129—135  ms)  and  77  ms  (95%  CI:  74—81  ms).  In  TZ,  cancers  had  signiﬁcantly  lower  T2  values
than normal  tissue  (P  =  0.008),  but  not  than  false  positive  ﬁndings.  Mean  T2  values  measured
on scanner  2  were  not  signiﬁcantly  different  than  those  measured  on  scanner  1  for  all  tissue
classes.
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Conclusion:  All  tested  tissue  classes  had  similar  mean  T2  values  on  both  scanners.  In  PZ,  the
T2 value  was  a  signiﬁcant  predictor  of  Gleason  ≥  7  cancers.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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Switzerland).  Suspicious  lesions  were  deﬁned  in  the  periph-
eral  zone  (PZ)  as  any  focal  lesion  showing  hyposignal  on  T2w
images  and/or  restriction  of  diffusion  on  apparent  diffusion
Table  1  Study  population.
Scanner  1  Scanner  2
Number  of
patients
67  16
Mean  age 63.1  (49—74)  60.8  (50—66)ultiparameric  MRI  (mp-MRI)  has  yielded  good  results  in
rostate  cancer  detection  and  localization  [1,2],  but  its
nterpretation  is  still  limited  by  a  lack  of  standardization.
ndeed,  characterization  of  focal  lesions  seen  on  prostate
p-MRI  remains  difﬁcult  because  of  the  overlap  between  the
ppearance  of  cancers  and  benign  conditions  and  because
he  different  pulse  sequences  that  compose  mp-MRI  may
ield  discordant  results  [2,3].  As  a  consequence,  the  good
esults  published  by  specialized  institutions  may  not  be
eproduced  by  less-experienced  radiologists  [4].
There  are  three  ways  to  improve  the  standardization  of
p-MRI  interpretation.  The  ﬁrst  one  is  to  establish  a  diag-
ostic  score  that  could  be  easily  used  by  all  readers.  The
uropean  Society  of  Urogenital  Radiology  has  recently  pro-
osed  the  so-called  PIRADS  score  [5],  but  two  recent  studies
ave  shown  that  inter-reader  agreement  remained  poor  to
oderate,  even  with  the  PIRADS  score  [6,7].  The  second
olution  is  to  develop  computer-aided  diagnosis  (CAD)  sys-
ems  that  could  assist  the  radiologist  [8,9].  However,  these
ystems  are  developed  only  in  specialized  institutions  and
re  not  widely  available.  The  third  solution  would  be  to  use
 quantitative  approach  for  mp-MRI  interpretation,  by  deﬁn-
ng  thresholds  for  quantitative  parameters  that  could  help
ssess  the  risk  of  malignancy  of  a  given  focal  lesion.  How-
ver,  quantiﬁcation  in  MRI  may  be  inﬂuenced  by  the  imaging
arameters  and  the  scanner  calibration  and  settings.  As
 result,  it  is  not  sure  that  one  can  deﬁne  quantitative
hresholds  that  may  be  reproducible  form  one  scanner  to
nother.
To  date,  little  has  been  published  on  the  role  of  the
easurement  of  the  T2  value  in  prostate  cancer  characteri-
ation  at  3  T  [10,11].  The  purpose  of  this  study  was  to  assess
hether  the  T2  value  was  a  signiﬁcant  predictor  of  malig-
ancy  and  to  evaluate  the  robustness  of  its  measure  on  two
ifferent  scanners  at  3  T.
aterial and methods
atient population
t  our  institution,  prostate  mp-MRI  is  part  of  the  usual
orkup  before  radical  prostatectomy.  Since  September
008,  all  patients  treated  by  radical  prostatectomy  who
ad  undergone  a  preoperative  mp-MRI  at  our  institution
ere  offered  to  have  their  data  entered  in  a  prospec-
ive  radio-pathological  correlation  database  [CorréLations
natomoRAdiologiques  en  IRM  de  Prostate  (CLARA-P)
atabase].  All  patients  entered  in  the  database  gave  writ-
en  consent  for  the  use  for  research  purposes  of  their  MR  and
athological  data  and  signed  the  Institutional  Review  Board-
pproved  consent  form.  The  database  was  also  registeredith  the  appropriate  administrative  authority  (Commission
ationale  de  l’Informatique  et  des  Libertés,  no  08-06).
For  the  present  study,  we  selected  from  the  database
he  patients  who  had  been  imaged  in  two  departments  of
adiology.  Department  1  used  a 3  T  General  Electric  scan-
er  (MR  750,  Milwaukee,  MI,  USA)  and  department  2  a  3  T
hilips  MR  scanner  (Achieva  Xseries,  Best,  The  Netherlands).
t  our  institution,  most  prostate  mp-MRIs  are  performed
n  department  1.  However,  some  patients  were  imaged
n  department  2,  mostly  for  practical  and  organizational
easons.  The  CLARA-P  database  contained  a  total  of  158
onsecutive  patients  imaged  at  3  T  on  scanner  1  or  2.
eventy-ﬁve  patients  were  excluded  because  the  multi-echo
equence  for  T2  mapping  had  not  been  acquired  (n  =  60)  or
ecause  T2  maps  were  of  poor  quality  (n  =  15).  This  left  a
tudy  population  of  83  patients.  Table  1  shows  their  mean
ge  and  PSA  level.
R protocol
or  both  scanners,  mp-MR  protocols  included  T2-weighted
T2w),  diffusion-weighted  (Dw)  and  dynamic  contrast-
nhanced  (DCE)  sequences,  as  well  as  a  multi-echo  sequence
or  T2  mapping  (Table  2).  T2  maps  were  calculated  from
onoexponential  decay  ﬁtting  of  the  multi-echo  datasets
sing  dedicated  vendors’  software.
T2w,  Dw,  DCE  and  T2  maps  axial  images  were  acquired
ith  the  same  position  and  slice  thickness  to  allow  direct
omparison  between  sequences.
R image analysis
he  mp-MRIs  of  the  patients  included  in  the  CLARA-P
atabase  were  reviewed  by  two  independent  radiologists
ith  11  years  and  1  year  of  experience  at  the  start  of  the
atabase  in  2008.  They  delineated  all  suspicious  lesions
isible  in  the  prostate  using  the  Osirix  freeware  (Osirix,(years)
Mean  PSA  level
(ng/mL)
8.26  (2.85—40)  10.52  (0.9—60)
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Table  2  Imaging  parameters.
Scanners  1  2
Manufacturer,
ﬁeld
strength
General  Electric  Medical  System,  3  T  Philips  Medical  Systems,  3  T
Model  name  Discovery  MR750  Achieva  3  T  Xseries
Receive  coil
type
32-channel  PPA  coil  16-channel  PPA  +  endorectal  coil
Sequence  T2w  Dw  DCE  T2  map T2w  Dw  DCE  T2  map
TR  (ms)  5000  5000  3.9  1900  5021  3925  4  4950
TE  (ms)  104  90  1.7  14,  28,
41,  55,
69,  83,
97,  110
120  70  2.3  25,  50,
75,  100,
125
FOV  (mm)  220  ×  220  380  ×  380  240  ×  192  300  ×  300  180  ×  180  180  ×  180  180  ×  180  180  ×  180
Acquisition
matrix
384  ×  256  128  ×  128  180  ×  160  320  ×  128  344  ×  255  116  ×  103  100  ×  100  104  ×  104
b-values
(s/mm2)
0, 2000  0,  800,
2000
Flip  angle
(degrees)
90/180  90  12  90/180  90/180  90  8  90/180
Slice  thickness
(mm)
3 3  3  3 3  3  3  3
Number  of
temporal
acq.
32 50
Temporal
resolution
(s)
7  5
c
e
o
l
l
i
p
f
u
a
b
T
i
w
s
C
T
a
was  computed  as  the  average  value  weighted  by  the  area  of
the  ROIs  delineated  on  each  individual  axial  slice.coefﬁcient  (ADC)  maps,  and/or  early  enhancement  on  DCE
images.  In  the  transition  zone  (TZ),  only  lesions  with  homo-
geneous  hyposignal,  no  capsule,  lenticular  or  amorphous
shape  and  involving  the  anterior  third  of  TZ  on  T2w  images
were  taken  into  consideration  [12—15].
Histopathological analysis
Whole-mount  sections  were  obtained  according  to  the  Stan-
ford  method  [16]  every  3  mm,  to  match  MR  slice  thickness.
Pathological  analysis  was  done  by  an  uropathologist  with
10  years  of  experience  at  the  start  of  the  database  in  2008.
All  tumors  with  in-plane  dimensions  >2  ×  2  mm2 and  a  Glea-
son  score  ≥  5  were  delineated  on  the  whole-mounts  glass
cover.  The  Gleason  score  of  all  individual  cancer  foci  was
assessed.
MR histological correlation
MR  images  and  whole-mounts  were  prospectively  compared
by  the  uropathologist  and  the  two  radiologists,  using  side-
by-side  comparison.  These  readers  reviewed  all  suspicious
lesions  in  mp-MRI  and  deﬁned  those  that  matched  can-
cer  foci  (true  positives),  and  those  that  corresponded  to
benign  conditions  (false  positives).  Then,  they  delineated
in  consensus  R0Is  that  were  as  close  as  possible  to  the  his-
tological  truth.  To  do  so,  they  modiﬁed,  when  needed,  the
delineation  of  true  positives  so  that  their  volume  and  shape
p
t
horrespond  to  those  of  histological  cancers.  They  also  delin-
ated  the  missed  cancers  that  were  retrospectively  seen
n  mp-MR  images  and  all  the  false  positives  noted  by  at
east  one  reader  of  the  CLARA-P  database.  All  the  ROIs  were
abelled  as  per  their  histological  nature  (cancer  or  false  pos-
tive).
Then,  one  researcher  with  one  year  of  experience  in
rostate  imaging  retrieved  the  delineations  of  cancers  and
alse  positive  lesions  and  copied  them  on  T2  maps  images
sing  the  Osirix  freeware.  He  delineated  the  rest  of  PZ
nd  TZ  that  did  not  contain  cancer  at  pathology  and  had
een  judged  as  normal  on  mp-MRI  by  the  two  radiologists.
hese  ROIs  will  be  referred  to  as  PZ  and  TZ  normal  tissue
n  the  rest  of  the  paper.  The  anterior  ﬁbromuscular  stroma
as  excluded  from  the  delineation  of  the  TZ  normal  tis-
ue.
omputation of T2 values
he  mean  T2  value  was  then  calculated  for  each  ROI.  When
 given  ROI  was  present  on  several  slices,  the  mean  T2  valueThus,  the  study  database  was  composed,  for  each
atient,  of  one  T2  value  for  PZ  normal  tissue,  TZ  normal
issue,  and  each  cancer  and  benign  false  positive  lesion  that
ad  been  delineated.
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Table  3  Mean  T2  values  of  the  different  classes  of  tissue  in  PZ  and  TZ.
Scanner  1  Scanner  2  P  value
n  T2  (ms) n T2  (ms)
PZ
Normal  tissue 67  139  ±  26 16 136  ±  31  0.88
False  positive 50  114  ±  17 21 124  ±  32  0.25
Cancers  84  107  ±  18 15 106  ±  26 0.97
TZ
Normal  tissue  67  96  ±  13  16  95  ±  17  0.99
False  positive  5  86  ±  15  6  104  ±  27  0.33
Cancers  15  85  ±  16  6  86  ±  8  0.67
P value tests the difference between the T2 values measured on the two scanners for each tissue class.
Table  4  Areas  under  the  receiver  operating  characteristic  curve  for  the  discrimination  of  cancers  in  patients  imaged  on
scanner  1.
Cancers  vs  normal  tissue  Cancers  vs  false  positive  lesions  Cancers  vs  normal  tissue  and  false  positive  lesions
PZ  0.83  (0.81—0.88)  0.74  (0.72—0.77)  0.76  (0.74—0.79)
TZ  0.79  (0.76—0.81)  ND  0.73  (0.71—0.76)
Intervals in brackets correspond to 95% conﬁdence intervals; ND: not determined.
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ferent  in  Gleason  ≤  6  cancers  and  in  false  positive  lesions
(P  =  0.73).  The  AUCs  for  discriminating,  using  the  mean  T2
value,  Gleason  ≥  7 cancers  among  all  cancers  and  among  all
Table  5  Mean  T2  values  of  PZ  cancers  as  a  function  of
their  Gleason  score.
Scanner  1  Scanner  2
N  T2  (ms)  N  T2  (ms)
PZ
GS  ≤  6  22  116  ±  23  4  123  ±  22
GS  =  7  46  105  ±  16  5  103  ±  26
GS  ≥  8  16  99  ±  13  6  97  ±  27
TZtatistical analysis
tatistical  analysis  was  performed  using  the  R  software
http://cran.r-project.org/).  Generalized  linear  mixed
odels  (GLMM)  were  used  to  quantify  the  ability  of  T2  value
o  discriminate  cancers  from  false  positive  lesions  and  Glea-
on  ≥  7  cancers  from  other  abnormal  mp-MRI  ﬁndings  (i.e.
alse  positive  lesions  +  Gleason  ≤  6  cancers).  Individual  ran-
om  effects  were  used  in  order  to  take  into  account  the
ntra-patient  correlation  structure.  The  likelihood  ratio  was
pplied  to  determine  the  signiﬁcance  of  the  model.  Regres-
ion  coefﬁcient  signiﬁcance  was  tested  using  the  Wald  test.
LMM  models  were  calculated  using  package  lme4.  The
ccuracy  of  the  model  was  measured  by  the  area  under  the
OC  curve  (AUC).  GLMM  predictions  and  AUC  were  calcu-
ated  using  package  ROCR.  Measures  obtained  on  scanners  1
nd  2  were  compared  with  the  Wilcoxon  non-parametric  test
hat  is  suitable  for  small  samples.  A  P  value  <  0.05  was  con-
idered  statistically  signiﬁcant  and  all  interval  estimations
iven  in  this  paper  are  95%  conﬁdence  intervals  (CI).
esults
2 values of the different types of prostate
issue measured on scanner 1
n  total,  288  ROIs  corresponding  to  cancers  (n  =  99),  benign
alse  positive  lesions  (n  =  55)  and  normal  tissue  (n  =  134)  were
elineated  in  patients  imaged  on  scanner  1.
Table  3  shows  the  mean  T2  values  measured  in  cancers,
alse  positive  lesions  and  normal  tissue  in  PZ  and  TZ.  In
Z,  the  mean  T2  value  was  signiﬁcantly  lower  in  cancershan  in  normal  tissue  (P  =  2  ×  10−9)  and  false  positive  lesions
P  =  0.02).  In  TZ,  the  mean  T2  value  was  also  signiﬁcantly
ower  in  cancers  than  in  normal  tissue  (P  =  0.008).  TZ  can-
ers  and  TZ  false  positive  lesions  were  not  compared  due  to
he  small  number  of  TZ  false  positive  lesions.
Table  4  shows  the  AUCs  for  discriminating,  using  the  mean
2  value,  cancers  from  normal  tissue,  false  positive  lesions
nd  the  overall  group  of  benign  tissue  (normal  tissue  +  false
ositive  lesions),  in  PZ  and  in  TZ.
Table  5  shows  the  mean  T2  values  in  cancers  as  a  func-
ion  of  their  Gleason  score  and  location.  In  PZ,  Gleason  ≥  7
ancers  had  signiﬁcantly  lower  mean  T2  than  Gleason  ≤  6
ancers  (P  =  0.009)  and  false  positive  lesions  (P  <  0.0003).
n  contrast,  the  mean  T2  value  was  not  signiﬁcantly  dif-GS  ≤  6  8  85  ±  20  4  90  ±  7
GS  =  7  6  81  ±  6  1  75
GS  ≥  8  1  106  1  82
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Figure 1. Images obtained in a 55-year-old man with a PSA level of 8.14 ng/mL and showing an axial T2-weighted (T2w) image (a), an
axial apparent diffusion coefﬁcient (ADC) map (b), an axial dynamic contrast-enhanced (DCE) image (c) and an axial T2 map  (d). All axial
images were obtained at the same slice level. Three suspicious lesions were noted. The ﬁrst one was in the left peripheral zone (PZ). It
was a 10-mm area with low signal intensity on T2w image (a, curve arrow), marked restriction of diffusion (b, curve arrow) and mild early
enhancement (c, curve arrow). Its mean T2 value (d, curve arrow) was 94.1 ms. It was a Gleason 7 cancer at pathology. The second lesion
was a 3-mm area of the right PZ, showing moderate restriction of diffusion (b, small arrow) and mild low signal intensity on T2w image (a,
small arrow). It was not visible at DCE imaging. Its mean T2 value (d, small arrow) was 111.5 ms. It was benign at pathology. The third lesion
was a 5-mm nodule with early enhancement (c, arrowhead), moderate restriction of diffusion (b, arrowhead) and mild low signal intensity
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I(a, arrowhead), located in the anterior third of the right transition
5 cancer at pathology.
suspicious  lesions  visible  on  mp-MRI  (i.e.  cancers  +  false  pos-
itive  lesions)  were  respectively  0.67  (95%CI:  0.65—0.7)  and
0.68  (95%CI:  0.65—0.72;  Fig.  1).
Figs.  2  and  3  respectively  show  the  overall  risk  of  malig-
nancy  and  the  risk  of  Gleason  ≥  7  malignancy  expressed  as
a  function  of  the  T2  value  in  the  population  of  suspicious
lesions  on  mp-MRI  (i.e  cancers  +  false  positive  lesions)  in  PZ.
The  T2  values  corresponding  to  an  overall  risk  of  malig-
nancy  of  25%  and  75%  were  respectively  176  ms  (95%CI:
162—183  ms)  and  85  ms  (95%CI:  80—90  ms).  The  T2  values
corresponding  to  a  risk  of  Gleason  ≥  7  malignancy  of  25%
and  75%  were  respectively  132  ms  (95%  CI:  129—135  ms)  and
77  ms  (95%  CI:  74—81  ms).
T2 values of the different types of prostate
tissue measured on scanner 2In  total,  80  ROIs  corresponding  to  cancers  (n  =  21),  benign
false  positive  lesions  (n  =  27)  and  normal  tissue  (n  =  32)  were
delineated  in  patients  imaged  on  scanner  2.
c
i
b
f. Its mean T2 value (d, small arrow) was 61.3 ms.  It was a Gleason
In  PZ,  the  mean  T2  value  was  signiﬁcantly  lower  in  can-
ers  than  in  normal  tissue  (P  =  0.006)  and  false  positive
esions  (P  =  0.045).  In  TZ,  it  was  lower  in  cancers  than  in
ormal  tissue,  but  not  signiﬁcantly  (P  =  0.07;  Table  3).
The  mean  T2  values  measured  on  scanner  2  in  cancers,
alse  positive  lesions  and  normal  tissue  were  similar  and
ot  signiﬁcantly  different  than  those  measured  on  scanner
,  neither  in  PZ  nor  in  TZ  (Table  3).  The  mean  T2  values
easured  on  both  scanners  in  Gleason  ≤  6,  Gleason  7  and
leason  ≥  8 cancers  were  similar  (Table  5);  the  difference
as  not  statistically  tested  due  to  the  small  number  of  can-
ers  imaged  on  scanner  2.
iscussion
deally,  a  quantitative  MR  parameter  used  for  prostate
ancer  detection  should  have  three  characteristics.  First,
t  should  signiﬁcantly  discriminate  prostate  cancer  from
enign  tissue.  Second,  it  should  distinguish  aggressive
rom  less  aggressive  tumors.  Finally,  it  should  show  little
370  
Figure 2. Curve showing the modeled risk of malignancy as a
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aunction of the T2 value. The black line indicates the mean risk
f malignancy. Red lines indicate the 95% conﬁdence interval of the
ean risk.
ependency  on  MR  protocol  settings  and  MR  vendors  so
hat  reliable  inter-institutions  thresholds  could  be  deﬁned
etween  malignant  and  benign  tissues  or  between  aggres-
ive  and  less  aggressive  tumors.  In  this  study,  we  assessed
hether  the  T2  value  fulﬁlled  these  three  conditions.
First,  in  agreement  with  several  other  studies  performed
t  1.5  T  [17—20]  or  at  3  T  [10],  we  found  the  T2  value  to  be
igniﬁcantly  lower  in  PZ  cancers  than  in  normal  PZ.  However,
o  be  useful  in  daily  practice,  the  T2  measurement  must  dis-
riminate  malignant  from  benign  tissue  in  the  subgroup  of
reas  appearing  suspicious  on  mp-MRI.  Liu  et  al.  assessed
igure 3. Curve showing the modeled risk of Gleason ≥ 7 malig-
ancy as a function of the T2 value. The black line indicates the
ean risk of malignancy. Red lines indicate the 95% conﬁdence
nterval of the mean risk.
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8  patients  with  31  suspicious  lesions  detected  on  3  T  mp-
RI  and  that  were  targeted  on  biopsy  [11].  The  T2  values  of
reas  positive  at  biopsy  (85—124  ms)  were  signiﬁcantly  lower
han  that  of  suspicious  areas  with  negative  biopsy  ﬁndings
83—168  ms,  P  <  0.05).  Our  results,  based  on  a  larger  popu-
ation  and  using  prostatectomy  specimens  as  gold  standard,
onﬁrm  that  the  T2  value  can  signiﬁcantly  discriminate  can-
ers  within  the  group  of  PZ  lesions  appearing  suspicious  at
p-MRI.
Second,  we  found  the  T2  value  to  be  signiﬁcantly  lower  in
leason  ≥  7  than  in  Gleason  ≤  6  cancers  in  PZ.  Only  one  study
valuated  the  potential  role  of  T2  measurement  in  assessing
umor  aggressiveness.  Gibbs  et  al.  showed  a trend  for
ecreasing  T2  with  increasing  Gleason  score  in  20  patients
reated  by  radical  prostatectomy  [10].  However,  the  differ-
nce  was  not  signiﬁcant,  probably  due  to  the  small  number
f  patients  evaluated.  Interestingly,  in  our  series,  we  found  a
omplete  overlap  between  the  T2  values  measured  in  Glea-
on  ≤  6  cancers  and  in  benign  false  positive  lesions.  Taken
ogether,  our  results  suggest  that  the  T2  value  could  be  used,
n  the  group  of  PZ  suspicious  areas  seen  on  mp-MRI,  as  an
ndicator  of  aggressive  tumors  rather  than  as  an  indicator
f  mere  malignancy.  This  ﬁnding  is  particularly  interest-
ng  in  the  current  context  of  emphasis  on  the  non-invasive
ssessment  of  prostate  cancer  aggressiveness  in  order  to
educe  over-detection  and  over-treatment  of  indolent  can-
ers  [21].
However,  T2  measurement  will  be  useful  in  clini-
al  practice  only  if  it  is  possible  to  deﬁne  quantitative
hresholds  between  tissue  classes.  For  that  purpose,  T2
easurement  needs  to  be  robust  to  changes  in  imaging
arameters  and  to  be  reproducible  from  one  scanner  to
nother.  Little  has  been  published  on  the  subject.  In  one
tudy,  a  second  T2  map  was  acquired  at  3  T  in  8  patients
hirty  minutes  after  a  ﬁrst  one.  Reproducibility  was  good,
ith  differences  between  the  two  measures  being,  on  aver-
ge,  less  than  2%  [11].  In  another  one,  performed  at  1.5  T,
3  patients  underwent  two  prostate  MRIs,  a  median  of  seven
ays  apart.  T2  measurements  were  found  to  be  highly  repro-
ucible,  with  a within-patient  coefﬁcient  of  variation  of
ess  than  4%  [22].  In  those  two  studies,  however,  the  imag-
ng  parameters  and  the  scanners  were  the  same  for  the
wo  measurements.  Our  study  brings  indirect  evidence  that
2  measurements  are  relatively  insensitive  to  changes  in
maging  protocols  or  MR  scanners.  First,  the  mean  T2  val-
es  measured  on  our  two  scanners  were  very  similar  for
ll  the  tested  classes  of  tissue,  despite  the  fact  that  the
wo  scanners  were  from  different  vendors  and  that  the  TE
elections  used  for  the  multi-echo  sequences  were  differ-
nt.  Second,  these  mean  T2  values  were  also  similar  to
hose  published  at  3  T  in  PZ  by  Liu  et  al.  using  accelerated
2  mapping  on  a  Philips  scanner  (normal  PZ:  149  ±  49  ms;
enign  suspicious  lesions:  114  ±  32  ms;  cancer:  100  ±  10  ms)
nd  by  Gibbs  et  al.  using  fast  spin  echo  on  a  GE  scanner  (nor-
al  PZ:  142  ±  24  ms;  cancer:  109  ±  20  ms)  [10,11]. However,
omparisons  of  mean  values  obtained  in  different  patients
ay  underestimate  the  variability  of  T2  measurement.  Only
 comparison  of  T2  values  obtained  on  the  same  patients
ith  two  different  scanners  could  assess  whether  meaning-
ul  inter-vendor  T2  thresholds  could  be  used  to  discriminate
enign  and  malignant  prostate  tissue  or  aggressive  and  less
:  A  m
T
i
p
o
s
p
t
t
D
T
c
R
[
[
[
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aggressive  tumors.  To  our  knowledge,  such  a  study  has  not
been  done  yet.
Even  if  the  T2  value  is  proved  in  the  future  to  be  insensi-
tive  to  the  imaging  parameters,  our  study  suggests  that  its
use  will  not  be  sufﬁcient  by  itself  to  adequately  characterize
focal  abnormalities  of  the  PZ.  Indeed,  modelled  T2  thresh-
olds  for  a  25%  risk  of  cancer  and  of  Gleason  ≥  7  cancer  were
176  and  132  ms,  respectively.  This  is  within  the  range  of  T2
values  measured  in  normal  PZ.  Similarly,  the  modelled  risk
of  cancer  and  of  Gleason  ≥  7  cancer  does  not  reach  90%  in
the  range  of  observed  T2  values  (Figs.  2  and  3).  This  indi-
cates  that  the  use  of  the  T2  value  as  a  stand-alone  cannot
deﬁnitively  ascertain  or  deﬁnitively  rule  out  cancer  or  even
Gleason  ≥  7  cancer.  This  is  in  line  with  the  abundant  body
of  literature  that  shows  that  a  multiparametric  approach  is
necessary  for  prostate  MRI  [5,23].  Thus,  other  quantitative
parameters  are  necessary  in  addition  to  the  T2  value  if  one
wants  to  exclusively  use  a  quantitative  approach  to  charac-
terize  prostate  cancer.  The  apparent  diffusion  coefﬁcient
(ADC),  some  semi-quantitative  enhancement  parameters
(e.g.,  peak  enhancement,  wash-in  and  wash-out  rates)  or
some  pharmacokinetic  parameters  (e.g.,  Ktrans  and  Kep)
have  been  shown  to  be  signiﬁcant  indicators  of  malig-
nancy  or  even  aggressive  malignancy  [24—31].  However,
they  depend  on  many  factors  related  to  the  imaging  protocol
(e.g.  b-values  selection  or  TE  for  ADC,  temporal  resolu-
tion  for  enhancement  and  pharmacokinetic  parameters),
the  model  used  for  analysis  or  even  the  patient  (e.g.,  car-
diac  output  or  hematocrit)  for  pharmacokinetic  parameters
[27,32—35].  Thus,  it  remains  unclear  whether  it  will  be  pos-
sible  or  not  to  use  reliable  diagnostic  thresholds  for  these
parameters,  even  with  standardized  protocols.  Nonetheless,
we  have  started  at  our  institution  a  systematic  study  of
all  factors  that  could  inﬂuence  diffusion  and  enhancement
parameters  in  order  to  further  explore  this  possibility.
The  T2  values  measured  in  suspicious  benign  lesions
and  in  cancers  in  TZ  were  similar,  suggesting  that  the  T2
will  not  be  a  useful  predictor  of  malignancy  in  TZ.  For-
tunately,  recent  works  showed  that  TZ  cancer  appearance
tended  to  be  monomorphic  on  T2w  imaging  with  homoge-
neous  hyposignal,  lack  of  capsule,  ill-deﬁned  boundaries,
amorphous  or  lenticular  shape  and  antero-apical  location
[12—15,36].  These  simple  criteria  provide  an  efﬁcient  char-
acterization  of  TZ  nodules  [15]  even  if  measuring  the  ADC
and  Ktrans  may  also  be  useful  [14].
Our  study  has  some  limitations.  First,  our  conclusions  are
limited  by  the  small  number  of  patients  imaged  on  scanner  2.
Second,  matching  mp-MRI  focal  lesions  with  corresponding
regions  on  whole-mounts  remains  difﬁcult  due  to  the  differ-
ence  in  angle  section  between  MR  images  and  whole-mounts.
Thus,  some  mismatches  might  have  occurred.  Third,  the
study  population  was  made  of  patients  treated  by  radi-
cal  prostatectomy.  Although  we  paid  attention  to  take  into
account  all  suspicious  lesions  visible  at  mp-MRI,  extrapola-
tion  of  our  results  to  other  populations  (e.g.,  candidates
to  biopsy  or  patients  under  active  surveillance)  may  not  be
appropriate.
In  conclusion,  we  found  the  T2  value  to  be  a  signiﬁ-
cant  predictor  of  aggressive  (Gleason  ≥  7)  tumors  at  3  T.  We
also  observed  similar  mean  T2  values  for  all  tested  tissue
classes  on  two  different  MR  scanners  from  different  vendors
using  non-standardized  imaging  protocols  for  T2  mapping.
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his  suggests  that  the  T2  value  may  be  robust  to  changes
n  protocols  and  MR  vendors.  However,  it  does  not  seem
ossible  to  deﬁnitively  ascertain  or  rule  out  the  presence
f  cancer  (or  Gleason  ≥  7  cancer)  using  the  T2  value  as  a
tand-alone.  Thus,  any  quantitative  approach  for  diagnosing
rostate  cancer  and  evaluating  its  aggressiveness  will  need
o  be  multiparametric  and  use  other  quantitative  parame-
ers.
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